Critical Reviews in Oncology / Hematology
Volume 75, Issue 1 , Pages 2-14 , July 2010

Angioprevention with fenretinide: Targeting angiogenesis in prevention and therapeutic strategies

  • Ilaria Sogno

      Affiliations

    • IRCCS MultiMedica, Milano, Italy
    • These authors equally contributed to this manuscript.
    • ,
  • Roberta Venè

      Affiliations

    • Molecular Oncology and Angiogenesis Laboratory, National Cancer Research Institute (IST), Genova, Italy
    • These authors equally contributed to this manuscript.
    • ,
  • Nicoletta Ferrari

      Affiliations

    • Molecular Oncology and Angiogenesis Laboratory, National Cancer Research Institute (IST), Genova, Italy
    • ,
  • Andrea De Censi

      Affiliations

    • Medical Oncology Unit, E.O. Ospedali Galliera, Genova, Italy
    • ,
  • Andrea Imperatori

      Affiliations

    • Center for Thoracic Surgery, University of Insubria, Varese, Italy
    • ,
  • Douglas M. Noonan

      Affiliations

    • IRCCS MultiMedica, Milano, Italy
    • Dept of Clinical and Biological Sciences, University of Insubria, Varese, Italy
    • Corresponding Author InformationCorresponding author at: Dipartimento di Scienze Cliniche e Biologiche Università degli Studi dell’Insubria, Via Ottorino Rossi, n.9, 21100 Varese, Italy. Tel.: +39 0332 217609; fax: +39 0332 217609.
    • ,
  • Francesca Tosetti

      Affiliations

    • Molecular Oncology and Angiogenesis Laboratory, National Cancer Research Institute (IST), Genova, Italy
    • These authors equally contributed to this manuscript.
    • ,
  • Adriana Albini

      Affiliations

    • IRCCS MultiMedica, Milano, Italy
    • These authors equally contributed to this manuscript.

,Accepted 29 October 2009.

References 

  1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  2. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62
  3. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res. 2009;15:5020–5025
  4. Albini A, Noonan DM. Rescuing COX-2 inhibitors from the waste bin. J Natl Cancer Inst. 2005;97:859–860
  5. Albini A, Pennesi G, Donatelli F, Cammarota R, Flora SD, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and Cardio-Oncological Prevention, J Natl Cancer Inst; in press.
  6. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;
  7. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7:139–147
  8. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002;16:2–14
  9. Ferrari N, Morini M, Pfeffer U, Minghelli S, Noonan DM, Albini A. Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clin Cancer Res. 2003;9:6020–6029
  10. Ferrari N, Pfeffer U, Dell’Eva R, Ambrosini C, Noonan DM, Albini A. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res. 2005;11:4610–4619
  11. Pienta KJ, Nguyen NM, Lehr JE. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res. 1993;53:224–226
  12. Tosetti F, Vene R, Arena G, et al. N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death. Mol Pharmacol. 2003;63:565–573
  13. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol. 2002;41:41–55
  14. Wake K. Sternzellen in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat. 1971;132:429–462
  15. Senoo H, Wake K. Suppression of experimental hepatic fibrosis by administration of vitamin A. Lab Invest. 1985;52:182–194
  16. Hixson EJ, Denine EP. Comparative subacute toxicity of all-trans- and 13-cis-retinoic acid in Swiss mice. Toxicol Appl Pharmacol. 1978;44:29–40
  17. Sabichi AL, Xu H, Fischer S, et al. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Clin Cancer Res. 2003;9:4606–4613
  18. Moon RC, Thompson HJ, Becci PJ, et al. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 1979;39:1339–1346
  19. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer in Lobund–Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res. 1991;51:3610–3611
  20. Conaway CC, Jiao D, Kelloff GJ, Steele VE, Rivenson A, Chung FL. Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and beta-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice. Cancer Lett. 1998;124:85–93
  21. Formelli F, Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res. 1993;53:5374–5376
  22. Orienti I, Zuccari G, Bergamante V, et al. Fenretinide–polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration. Biomacromolecules. 2007;8:3258–3262
  23. Okuda T, Kawakami S, Higuchi Y, et al. Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. Int J Pharm. 2009;373:100–106
  24. Orienti I, Zuccari G, Carosio R, Montaldo PG. Improvement of aqueous solubility of fenretinide and other hydrophobic anti-tumor drugs by complexation with amphiphilic dextrins. Drug Deliv. 2009;16:389–398
  25. Albini A, D’Agostini F, Giunciuglio D, Paglieri I, Balansky R, De Flora S. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer. 1995;61:121–129
  26. Cai T, Fassina G, Morini M, et al. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest. 1999;79:1151–1159
  27. Albini A, Morini M, D’Agostini F, et al. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res. 2001;61:8171–8178
  28. De Flora S, D’Agostini F, Masiello L, Giunciuglio D, Albini A. Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. Int J Cancer. 1996;67:842–848
  29. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18:349–355
  30. Sozzani S, Rusnati M, Riboldi E, Mitola S, Presta M. Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol. 2007;28:385–392
  31. Villablanca EJ, Zhou D, Valentinis B, et al. Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo. J Leukoc Biol. 2008;84:871–879
  32. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer. 2006;13:51–68
  33. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91:1847–1856
  34. De Palo G, Mariani L, Camerini T, et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol. 2002;86:24–27
  35. Formelli F, Meneghini E, Cavadini E, et al. Plasma retinol and prognosis of postmenopausal breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2009;18:42–48
  36. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol. 2006;17:1065–1071
  37. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997;18:801–831
  38. Decensi A, Veronesi U, Miceli R, et al. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res. 2003;9:4722–4729
  39. Tu Y, Jerry DJ, Pazik B, Smith Schneider S. Sensitivity to DNA damage is a common component of hormone-based strategies for protection of the mammary gland. Mol Cancer Res. 2005;3:435–442
  40. Simeone AM, Deng CX, Kelloff GJ, Steele VE, Johnson MM, Tari AM. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis. 2005;26:1000–1007
  41. Turton JA, Willars GB, Haselden JN, Ward SJ, Steele CE, Hicks RM. Comparative teratogenicity of nine retinoids in the rat. Int J Exp Pathol. 1992;73:551–563
  42. Fontana JA. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol. 1987;55:136–144
  43. Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. 1989;49:4472–4476
  44. Cope MB, Steele VE, Lubet RA, et al. Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention. Oncol Rep. 2004;11:465–469
  45. Anzano MA, Byers SW, Smith JM, et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 1994;54:4614–4617
  46. Anzano MA, Peer CW, Smith JM, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst. 1996;88:123–125
  47. Guerrieri-Gonzaga A, Robertson C, Bonanni B, et al. Preliminary results on safety and activity of a randomized, double-blind, 2×2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol. 2006;24:129–135
  48. Decensi A, Bonanni B, Baglietto L, et al. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res. 2004;10:4389–4397
  49. Decensi A, Robertson C, Guerrieri-Gonzaga A, et al. Randomized double-blind 2×2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol. 2009;27:3749–3756
  50. Garaventa A, Luksch R, Lo Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res. 2003;9:2032–2039
  51. Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res. 1998;4:1345–1355
  52. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res. 2000;6:2973–2979
  53. Schneider BJ, Worden FP, Gadgeel SM, et al. Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs. 2009;
  54. Tosetti F, Noonan DM, Albini A. Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals. Int J Cancer. 2009;125:1997–2003
  55. Lovat PE, Ranalli M, Corazzari M, et al. Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. J Cell Biochem. 2003;89:698–708
  56. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J Natl Cancer Inst. 1999;91:1138–1146
  57. Raffaghello L, Pagnan G, Pastorino F, et al. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int J Cancer. 2003;104:559–567
  58. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am. 2001;15:867–910
  59. Montaldo PG, Pagnan G, Pastorino F, et al. N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death. Int J Cancer. 1999;81:262–267
  60. Puduvalli VK, Saito Y, Xu R, Kouraklis GP, Levin VA, Kyritsis AP. Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res. 1999;5:2230–2235
  61. Puduvalli VK, Li JT, Chen L, McCutcheon IE. Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res. 2005;65:1547–1553
  62. Dmitrovsky E. Fenretinide activates a distinct apoptotic pathway. J Natl Cancer Inst. 2004;96:1264–1265
  63. Bu P, Wan YJ. Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent. BMC Cancer. 2007;7:236
  64. Sabichi AL, Hendricks DT, Bober MA, Birrer MJ. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst. 1998;90:597–605
  65. Hail N, Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide. J Biol Chem. 2001;276:45614–45621
  66. Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res. 1999;59:2493–2498
  67. Suzuki S, Higuchi M, Proske RJ, Oridate N, Hong WK, Lotan R. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene. 1999;18:6380–6387
  68. Ulukaya E, Pirianov G, Kurt MA, Wood EJ, Mehmet H. Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation. Cell Death Differ. 2003;10:856–859
  69. Lovat PE, Ranalli M, Annichiarrico-Petruzzelli M, et al. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp Cell Res. 2000;260:50–60
  70. Cuperus R, Tytgat GA, Leen R, et al. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. Int J Oncol. 2008;32:1011–1019
  71. Kadara H, Tahara E, Kim HJ, Lotan D, Myers J, Lotan R. Involvement of Rac in fenretinide-induced apoptosis. Cancer Res. 2008;68:4416–4423
  72. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst. 2008;100:580–595
  73. Appierto V, Tiberio P, Villani MG, Cavadini E, Formelli F. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis. 2009;30:824–831
  74. Hill DS, Martin S, Armstrong JL, et al. Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma. Clin Cancer Res. 2009;15:1192–1198
  75. Pagnan G, Di Paolo D, Carosio R, et al. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res. 2009;15:1199–1209
  76. Kohno K. How transmembrane proteins sense endoplasmic reticulum stress. Antioxid Redox Signal. 2007;9:2295–2303
  77. Lai WL, Wong NS. The PERK/eIF2 alpha signaling pathway of unfolded protein response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells. Exp Cell Res. 2008;314:1667–1682
  78. DiPietrantonio AM, Hsieh TC, Juan G, Traganos F, Darzynkiewicz Z, Wu JM. Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res. 2000;60:4331–4335
  79. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res. 2004;64:5415–5424
  80. Erdreich-Epstein A, Tran LB, Bowman NN, et al. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem. 2002;277:49531–49537
  81. Lovat PE, Di Sano F, Corazzari M, et al. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst. 2004;96:1288–1299
  82. O’Donnell PH, Guo WX, Reynolds CP, Maurer BJ. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia. 2002;16:902–910
  83. Wang H, Maurer BJ, Reynolds CP, Cabot MC. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res. 2001;61:5102–5105
  84. Guilbault C, De Sanctis JB, Wojewodka G, et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol. 2008;38:47–56
  85. Guilbault C, Wojewodka G, Saeed Z, et al. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol. 2009;41:100–106
  86. Boya P, Morales MC, Gonzalez-Polo RA, et al. The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Oncogene. 2003;22:6220–6230
  87. Chen YR, Zhou G, Tan TH. c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide. Mol Pharmacol. 1999;56:1271–1279
  88. Appierto V, Villani MG, Cavadini E, Lotan R, Vinson C, Formelli F. Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ. 2004;11:270–279
  89. Lovat PE, Oliverio S, Corazzari M, et al. Induction of GADD153 and Bak: novel molecular targets of fenretinide-induced apoptosis of neuroblastoma. Cancer Lett. 2003;197:157–163
  90. Cuello M, Coats AO, Darko I, et al. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ. 2004;11:527–541
  91. Vene R, Arena G, Poggi A, et al. Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications. Mol Cancer Ther. 2007;6:286–298
  92. Schroeder CP, Kadara H, Lotan D, et al. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res. 2006;66:9762–9770
  93. Muller A, Nakagawa H, Rustgi AK. Retinoic acid and N-(4-hydroxy-phenyl) retinamide suppress growth of esophageal squamous carcinoma cell lines. Cancer Lett. 1997;113:95–101
  94. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr. 2000;130:479S–482S
  95. Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 2001;97:3919–3924
  96. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am J Pathol. 1996;149:247–258
  97. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res. 1998;58:5551–5558
  98. Iurlaro M, Benelli R, Masiello L, Rosso M, Santi L, Albini A. Beta Interferon inhibits HIV-1 Tat-induced angiogenesis: synergism with 13-cis retinoic acid. Eur J Cancer. 1998;34:570–576
  99. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 2001;61:1477–1485
  100. Ribatti D, Alessandri G, Baronio M, et al. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer. 2001;94:314–321
  101. Ribatti D, Raffaghello L, Marimpietri D, et al. Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Lett. 2003;197:181–184
  102. Simile MM, Pagnan G, Pastorino F, et al. Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-{kappa}B and Mat1A genes in the early stages of rat liver carcinogenesis. Carcinogenesis. 2005;26:417–427
  103. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W. Retinoids, interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett. 1995;89:117–124
  104. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563–566
  105. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene. 2003;22:6589–6597
  106. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:435–444
  107. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002;277:38205–38211
  108. Stoeltzing O, Liu W, Reinmuth N, et al. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol. 2003;163:1001–1011
  109. Torrisi R, Parodi S, Fontana V, et al. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int J Cancer. 1998;76:787–790
  110. Serrano D, Baglietto L, Johansson H, et al. Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer. Clin Cancer Res. 2005;11:2083–2088
  111. Favoni RE, de Cupis A, Bruno S, et al. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br J Cancer. 1998;77:2138–2147
  112. Erdreich-Epstein A, Shimada H, Groshen S, et al. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 2000;60:712–721
  113. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol. 2003;13:159–167
  114. Lopez-Hernandez FJ, Ortiz MA, Bayon Y, Piedrafita FJ. Reduced concentrations of serum enhance the antiproliferative activity of retinoid-related molecules and accelerate the onset of apoptosis. Biochem Pharmacol. 2003;65:2021–2030
  115. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444:761–765
  116. Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med. 2003;9:1033–1038
  117. Qiu T, Grizzle WE, Oelschlager DK, Shen X, Cao X. Control of prostate cell growth: BMP antagonizes androgen mitogenic activity with incorporation of MAPK signals in Smad1. EMBO J. 2007;26:346–357
  118. Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res. 2006;66:11089–11093
  119. Lotan R. Retinoids as modulators of tumor cells invasion and metastasis. Semin Cancer Biol. 1991;2:197–208
  120. Bollag W, Majewski S, Jablonska S. Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia. 1994;8:1453–1457
  121. Shaker MR, Yang G, Timme TL, et al. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis. 2000;18:429–438
  122. Pollard M, Luckert PH. The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund–Wistar rats. Cancer Lett. 1991;59:159–163
  123. Takahashi N, Tamagawa K, Shimizu K, Fukui T, Maitani Y. Effects on M5076-hepatic metastasis of retinoic acid and N-(4-hydroxyphenyl) retinamide, fenretinide entrapped in SG-liposomes. Biol Pharm Bull. 2003;26:1060–1063
  124. Kim JH, Tanabe T, Chodak GW, Rukstalis DB. In vitro anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on human prostatic adenocarcinoma. Anticancer Res. 1995;15:1429–1434
  125. Simeone AM, Colella S, Krahe R, Johnson MM, Mora E, Tari AM. N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells. Carcinogenesis. 2006;27:568–577
  126. Um SJ, Lee SY, Kim EJ, et al. Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells. Cancer Lett. 2001;174:127–134
  127. Um SJ, Sin HS, Han HS, et al. Potent cytotoxic effects of novel retinamide derivatives in ovarian cancer cells. Biol Pharm Bull. 2003;26:1412–1417
  128. Golubkov V, Garcia A, Markland FS. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res. 2005;25:249–253
  129. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res. 2005;65:9555–9565
  130. Albini A, Tosetti F, Benelli R, Noonan DM. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res. 2005;65:10637–10641
  131. Vaccari M, Silingardi P, Argnani A, et al. In vitro effects of fenretinide on cell-matrix interactions. Anticancer Res. 2000;20:3059–3066
  132. Webber MM, Bello-DeOcampo D, Quader S, Deocampo ND, Metcalfe WS, Sharp RM. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin Exp Metastasis. 1999;17:255–263
  133. Rozzo C, Chiesa V, Caridi G, Pagnan G, Ponzoni M. Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Int J Cancer. 1997;70:688–698
  134. Panigone S, Bergomas R, Fontanella E, et al. Up-regulation of prosaposin by the retinoid HPR and its effect on ceramide production and integrin receptors. FASEB J. 2001;15:1475–1477

PII: S1040-8428(09)00221-2

doi: 10.1016/j.critrevonc.2009.10.007

Critical Reviews in Oncology / Hematology
Volume 75, Issue 1 , Pages 2-14 , July 2010

Article Tools

* Image Usage & Resolution